174 related articles for article (PubMed ID: 26162493)
1. Efficient detection of frequent eIF2B mutations for the rapid molecular diagnosis of CACH/VWM syndrome.
Ferreira MC; Dorboz I; Boespflug-Tanguy O
Clin Biochem; 2015 Dec; 48(18):1317-23. PubMed ID: 26162493
[TBL] [Abstract][Full Text] [Related]
2. A yeast purification system for human translation initiation factors eIF2 and eIF2Bε and their use in the diagnosis of CACH/VWM disease.
de Almeida RA; Fogli A; Gaillard M; Scheper GC; Boesflug-Tanguy O; Pavitt GD
PLoS One; 2013; 8(1):e53958. PubMed ID: 23335982
[TBL] [Abstract][Full Text] [Related]
3. [Three-dimensional Structure of eIF2B: A Clue to Understanding the Pathogenesis of CACH/VWM Disease].
Kashiwagi K; Ito T; Yokoyama S
Brain Nerve; 2017 Jan; 69(1):45-50. PubMed ID: 28126977
[TBL] [Abstract][Full Text] [Related]
4. Biochemical effects of mutations in the gene encoding the alpha subunit of eukaryotic initiation factor (eIF) 2B associated with Vanishing White Matter disease.
Wortham NC; Proud CG
BMC Med Genet; 2015 Aug; 16():64. PubMed ID: 26285592
[TBL] [Abstract][Full Text] [Related]
5. Glial pathology in a novel spontaneous mutant mouse of the Eif2b5 gene: a vanishing white matter disease model.
Terumitsu-Tsujita M; Kitaura H; Miura I; Kiyama Y; Goto F; Muraki Y; Ominato S; Hara N; Simankova A; Bizen N; Kashiwagi K; Ito T; Toyoshima Y; Kakita A; Manabe T; Wakana S; Takebayashi H; Igarashi H
J Neurochem; 2020 Jul; 154(1):25-40. PubMed ID: 31587290
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of mutations for the diagnosis of vanishing white matter disease.
Scali O; Di Perri C; Federico A
Neurol Sci; 2006 Sep; 27(4):271-7. PubMed ID: 16998732
[TBL] [Abstract][Full Text] [Related]
7. Vanishing white matter: deregulated integrated stress response as therapy target.
Abbink TEM; Wisse LE; Jaku E; Thiecke MJ; Voltolini-González D; Fritsen H; Bobeldijk S; Ter Braak TJ; Polder E; Postma NL; Bugiani M; Struijs EA; Verheijen M; Straat N; van der Sluis S; Thomas AAM; Molenaar D; van der Knaap MS
Ann Clin Transl Neurol; 2019 Aug; 6(8):1407-1422. PubMed ID: 31402619
[TBL] [Abstract][Full Text] [Related]
8. Heightened stress response in primary fibroblasts expressing mutant eIF2B genes from CACH/VWM leukodystrophy patients.
Kantor L; Harding HP; Ron D; Schiffmann R; Kaneski CR; Kimball SR; Elroy-Stein O
Hum Genet; 2005 Oct; 118(1):99-106. PubMed ID: 16041584
[TBL] [Abstract][Full Text] [Related]
9. Exon deletion in the non-catalytic domain of eIF2Bepsilon due to a splice site mutation leads to infantile forms of CACH/VWM with severe decrease of eIF2B GEF activity.
Horzinski L; Gonthier C; Rodriguez D; Scherer C; Boespflug-Tanguy O; Fogli A
Ann Hum Genet; 2008 May; 72(Pt 3):410-5. PubMed ID: 18294360
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the genes encoding eukaryotic translation initiation factor 2B in Japanese patients with vanishing white matter disease.
Shimada S; Shimojima K; Sangu N; Hoshino A; Hachiya Y; Ohto T; Hashi Y; Nishida K; Mitani M; Kinjo S; Tsurusaki Y; Matsumoto N; Morimoto M; Yamamoto T
Brain Dev; 2015 Nov; 37(10):960-6. PubMed ID: 25843247
[TBL] [Abstract][Full Text] [Related]
11. [CACH/VWM syndrome and leucodystrophies related to EIF2B mutations].
Labauge P; Fogli A; Niel F; Rodriguez D; Boespflug-Tanguy O
Rev Neurol (Paris); 2007 Sep; 163(8-9):793-9. PubMed ID: 17878805
[TBL] [Abstract][Full Text] [Related]
12. Ovarioleukodystrophy due to EIF2B5 mutations.
Ibitoye RT; Renowden SA; Faulkner HJ; Scolding NJ; Rice CM
Pract Neurol; 2016 Dec; 16(6):496-499. PubMed ID: 27651498
[TBL] [Abstract][Full Text] [Related]
13. [Eukaryotic translation initiation factor 2B and leukoencephalopathy with vanishing white matter].
Pan YX; Wu Y; Niu ZP; Jiang YW
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):608-10. PubMed ID: 19829687
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel EIF2B mutations in Chinese patients with vanishing white matter disease.
Wu Y; Pan Y; Du L; Wang J; Gu Q; Gao Z; Li J; Leng X; Qin J; Wu X; Jiang Y
J Hum Genet; 2009 Feb; 54(2):74-7. PubMed ID: 19158808
[TBL] [Abstract][Full Text] [Related]
15. Identification of ten novel mutations in patients with eIF2B-related disorders.
Ohlenbusch A; Henneke M; Brockmann K; Goerg M; Hanefeld F; Kohlschütter A; Gärtner J
Hum Mutat; 2005 Apr; 25(4):411. PubMed ID: 15776425
[TBL] [Abstract][Full Text] [Related]
16. A Japanese girl with an early-infantile onset vanishing white matter disease resembling Cree leukoencephalopathy.
Takano K; Tsuyusaki Y; Sato M; Takagi M; Anzai R; Okuda M; Iai M; Yamashita S; Okabe T; Aida N; Tsurusaki Y; Saitsu H; Matsumoto N; Osaka H
Brain Dev; 2015 Jun; 37(6):638-42. PubMed ID: 25457085
[TBL] [Abstract][Full Text] [Related]
17. The large spectrum of eIF2B-related diseases.
Fogli A; Boespflug-Tanguy O
Biochem Soc Trans; 2006 Feb; 34(Pt 1):22-9. PubMed ID: 16246171
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the endoplasmic reticulum-stress response in eIF2B-mutated lymphocytes and lymphoblasts from CACH/VWM patients.
Horzinski L; Kantor L; Huyghe A; Schiffmann R; Elroy-Stein O; Boespflug-Tanguy O; Fogli A
BMC Neurol; 2010 Oct; 10():94. PubMed ID: 20958979
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic initiation factor 2B (eIF2B) GEF activity as a diagnostic tool for EIF2B-related disorders.
Horzinski L; Huyghe A; Cardoso MC; Gonthier C; Ouchchane L; Schiffmann R; Blanc P; Boespflug-Tanguy O; Fogli A
PLoS One; 2009 Dec; 4(12):e8318. PubMed ID: 20016818
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
